Aug. 11 at 2:54 PM
$BDTX market is already pricing a failure of the glioblastoma trial(just because no biotech suceeded in the past).
But here we have a specific target , a brain penetrant medicine,and most important Silevertinib forms a strong covalent bond that prevents the paradoxical activation in glioblastoma( which is what had the previous meds fail).
Dr. Patrick Wen is conducting the phase 2 trial started in may( and he he hands down the best in the world, dana farber director of neuro oncology ,harvar med school). If this will work its gonna be a great news for stockholder and mostly for patients.
